Articles related to ANTIDEPRESSANTS

Studies have shown a mean effect size with CBTI of 0.96 compared with 0.87 for pharmacotherapy, suggesting similar efficacy in short term but CBTI seems to have longer-lasting effects.

Treatment preferences shifted to include nonaugmentative antidepressants and electroconvulsive therapy based on changes in patient characteristics.

The historical use of classic monoamine oxidase inhibitors (MAOIs) is overviewed, with consideration given to their efficacy and safety before discussing the importance of reassessing their place in current treatment algorithms.

Among those treated with the drug combination, 18 to 22 out of every 100 residents had a seizure within one year, compared to fewer than two per 100 in the general nursing home population.

N-nitroso-duloxetine poses increased cancer risk at higher concentrations and extended exposure periods, prompting FDA-mandated strict limits on nitrosamine levels in medications.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”